India's First Indigenous mRNA Vaccine for Tuberculosis Enters Phase III Trials
India's first indigenous mRNA-based vaccine for Tuberculosis (TB) has successfully entered Phase III clinical trials.
2-Minute Summary (TL;DR)
- India's first indigenous mRNA vaccine for Tuberculosis (TB) has entered Phase III clinical trials.
- The vaccine utilizes messenger RNA (mRNA) technology, similar to some COVID-19 vaccines.
- Phase III trials involve over 10,000 volunteers across multiple sites to assess efficacy and safety.
- The development is a collaborative effort involving ICMR, NIV, and Gennova Biopharmaceuticals Ltd.
- This vaccine aims to provide better protection against TB, potentially replacing the century-old BCG vaccine.
- It could play a crucial role in combating drug-resistant TB strains.
- The initiative strongly supports India's 'TB Mukt Bharat' mission targeting TB elimination by 2025.
- Successful development will boost India's self-reliance in advanced vaccine technology ('Atmanirbhar Bharat').
How This Topic is Tested in Competitive Exams
| Exam | Frequency | Approx. Marks | What Gets Asked |
|---|---|---|---|
| SSC (CGL / CHSL / MTS) | High | 4–8 | Basic science, space missions, ISRO launches, and defence technology are standard SSC GK topics. |
| UPSC / State PCS | Medium | 5–8 | UPSC tests Science & Technology through governance: space policy, biotech regulations, cyber security. |
| Railway (RRB NTPC / Group D) | Very High | 6–10 | Science and Technology is one of the largest GK sections in Railway papers. |
| State PCS / PSC | Medium | 3–5 | Space missions, defence acquisitions, and health research appear regularly. |
Key Facts to Remember: India's First Indigenous mRNA Vaccine for Tuberculosis Enters Phase III Trials
- India's first indigenous mRNA vaccine for Tuberculosis (TB) has entered Phase III clinical trials.
- The vaccine utilizes messenger RNA (mRNA) technology, similar to some COVID-19 vaccines.
- Phase III trials involve over 10,000 volunteers across multiple sites to assess efficacy and safety.
- The development is a collaborative effort involving ICMR, NIV, and Gennova Biopharmaceuticals Ltd.
- This vaccine aims to provide better protection against TB, potentially replacing the century-old BCG vaccine.
- It could play a crucial role in combating drug-resistant TB strains.
- The initiative strongly supports India's 'TB Mukt Bharat' mission targeting TB elimination by 2025.
- Successful development will boost India's self-reliance in advanced vaccine technology ('Atmanirbhar Bharat').
Practice Questions
Q1. What is the primary technology employed in India's first indigenous mRNA vaccine for Tuberculosis?
- Viral Vector Technology
- Messenger RNA (mRNA) Technology
- Subunit Vaccine Technology
- Inactivated Virus Technology
Explanation: The vaccine uses messenger RNA (mRNA) technology, which instructs the body's cells to produce specific proteins that trigger an immune response against the TB pathogen. This technology gained prominence with COVID-19 vaccines.
Q2. Which of the following is a primary goal of India's 'TB Mukt Bharat' mission?
- To reduce TB mortality by 50% by 2030
- To eliminate Tuberculosis from India by 2025
- To develop a universal TB diagnostic test
- To increase BCG vaccination coverage to 95%
Explanation: The 'TB Mukt Bharat' mission is a flagship public health initiative by the Indian government with the ambitious target of eliminating Tuberculosis from the country by the year 2025.
Q3. The Phase III clinical trials for the indigenous mRNA TB vaccine involve approximately how many volunteers?
- 1,000
- 5,000
- 10,000
- 25,000
Explanation: The Phase III trials are designed to be large-scale and comprehensive, involving over 10,000 volunteers across multiple study sites to rigorously evaluate the vaccine's efficacy and safety in a diverse population.
Q4. Which Indian organizations are key collaborators in the development of this indigenous mRNA TB vaccine?
- AIIMS and DRDO
- ICMR and NIV
- CSIR and DBT
- NITI Aayog and WHO India
Explanation: The development of the indigenous mRNA TB vaccine is a collaborative effort primarily involving the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), along with a private biotech firm.
Q5. What is a potential significant advantage of the new mRNA TB vaccine over the existing BCG vaccine?
- It is cheaper to produce
- It offers better protection against pulmonary TB in adults
- It can be administered orally
- It provides lifelong immunity
Explanation: The BCG vaccine, while important, has shown variable efficacy in preventing pulmonary TB in adults. The new mRNA vaccine aims to offer more robust and potentially broader protection, particularly against the adult form of the disease.
How to Prepare Science & Technology for Government Exams — India's First Indigenous mRNA Vaccine for Tubercu…
For Railway exams, make flashcards for every major ISRO launch — name, payload, purpose, date. These repeat frequently.
For SSC, focus on defence acquisitions and their strategic significance rather than technical specs.
For UPSC, connect every scientific development to policy — climate targets, digital India, health policy.
Related Current Affairs
Test Your Knowledge on Today's Current Affairs
10 questions · 10 minutes · Based on today's GK updates. See how prepared you really are.
Start Daily Quiz